胶质母细胞瘤自适应放疗的疗效与复发模式
该回顾性队列纳入59例病理确诊的胶质母细胞瘤患者,接受术后三维适形放疗为基础的自适应放疗(ART),于34–36 Gy后行中期MRI并制定单次离线补量计划。中位随访19.2个月,中位总生存26.6个月、中位无进展生存10.5个月,复发以中心性为主(78%),未见边缘复发,≥2级放射性坏死未见。
要点
- 中位OS 26.6个月,1年与2年OS率分别为93.9%和54.6%。
- 复发以中心性为主(29例,78%),未见边缘复发。
- 未观察到≥2级放射性坏死,仅2例1级放射性坏死。
核心结论
- 胶质母细胞瘤自适应放疗与较好的生存结局和低毒性相关,不增加边缘复发风险,放射性坏死发生率低。
研究设计与样本
- 放疗中期在给予34–36 Gy后行MRI,据此生成单次离线ART补量计划。
- 放疗方案为初始靶区40 Gy分20次,随后补量20 Gy分10次,总量60 Gy分30次、共六周。
- 采用Kaplan–Meier法估计无进展生存(PFS)与总生存(OS);按复发肿瘤体积与95%等剂量线空间关系分类复发模式。
主要发现
- 中位随访19.2个月(范围2.1–81.6),36例(61.0%)复发,32例(54.2%)死亡。
- 1年与2年OS率分别为93.9%和54.6%,中位OS 26.6个月。
- 6个月与12个月PFS率分别为71.1%和46.1%,中位PFS 10.5个月。
- 中心性复发29例(78%),远处复发5例(14%),野内复发3例(8%),未见边缘复发。
- 未观察到≥2级放射性坏死,仅2例1级放射性坏死。
关键数值与推荐
- 复发模式分类依据复发肿瘤体积与95%等剂量线的空间关系。
- 中心性复发29例(78%)、远处复发5例(14%)、野内复发3例(8%),边缘复发未观察到。
临床怎么用
- GBM术后放疗可考虑基于中期MRI的离线单次自适应补量,以兼顾生存获益与低毒性。
- 关注中心性复发为主的模式,随访影像需重点评估95%等剂量线内区域。
局限性
- 回顾性设计、单中心、样本量59例,随访时间有限。
- 需进一步研究优化ART流程以最大化临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma (GBM) is an aggressive primary brain tumor with a high recurrence rate despite multimodal treatment approaches. Adaptive radiation therapy (ART) involves adjusting the treatment plan based on tumor and resection cavity changes during radiotherapy, potentially improving treatment precision while reducing radiation exposure to normal brain tissue. However, the clinical outcomes and recurrence patterns associated with ART remain unclear. We aimed to evaluate the efficacy of ART for GBM treatment, focusing on survival outcomes and recurrence patterns. METHODS: We retrospectively analyzed a prospectively collected cohort of 59 patients with pathologically confirmed GBM who received postoperative three-dimensional conformal radiotherapy (3D-CRT)–based ART between April 2015 and November 2018. Mid-treatment magnetic resonance imaging was performed after delivery of 34–36 Gy. Based on these images, an offline single-time-point ART boost plan was generated to accommodate changes in tumor size and the resection cavity. Radiotherapy consisted of 40 Gy in 20 fractions to the initial target, followed by a 20 Gy boost in f10 fractions (total 60 Gy in 30 fractions over six weeks). Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method. Recurrence patterns were classified by the spatial relationship between recurrent tumor volume and the 95% isodose line. RESULTS: During a median follow-up period of 19.2 (range, 2.1–81.6) months, 36 patients (61.0%) experienced tumor recurrence, and 32 (54.2%) died. The 1- and 2-year OS rates were 93.9% and 54.6%, respectively, with a median OS of 26.6 months. The 6- and 12-month PFS rates were 71.1% and 46.1%, respectively, with a median PFS of 10.5 months. Central recurrence was the most common pattern (29 patients, 78%), followed by distant (5 patients, 14%) and in-field recurrences (3 patients, 8%). Marginal recurrence was not observed. No cases of grade 2 or higher radiation necrosis were observed, and only two cases of grade 1 radiation necrosis were identified. CONCLUSIONS: ART for GBM is associated with favorable survival outcomes and low toxicity. ART does not increase the risk of marginal recurrence, and the incidence of radiation necrosis is low. Further studies are required to optimize ART protocols to maximize their clinical benefits.
引用
- Matsuyama T, Yamada S, Otsuka H, et al. Adaptive radiation therapy for glioblastoma: clinical efficacy and recurrence patterns. Radiat Oncol. 2025. PMID: 41390433. doi:10.1186/s13014-025-02778-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。